Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Completed 9Active not recruiting 3Unknown 2

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Fallopian Tube Neoplasms 4Ovarian Neoplasms 3Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Solitary Fibrous Tumor, Pleural 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Leiomyosarcoma 1Glioblastoma 1Fallopian Tube Mucinous Adenocarcinoma 1Colorectal Neoplasms 1Carcinosarcoma 1Carcinoma, Endometrioid 1

Interventions

pembrolizumab 24Carboplatin 21Paclitaxel 20olaparib 19Magnetic Resonance Spectroscopy 14Bevacizumab 14Cyclophosphamide 12Specimen Handling 11Nivolumab 11Gemcitabine 11Taxes 10niraparib 8Cisplatin 8Biopsy 8liposomal doxorubicin 7fludarabine 7Surveys and Questionnaires 6Immunoglobulin G 6Doxorubicin 6Disulfides 6durvalumab 5palbociclib 4oregovomab 4X-Rays 4Ipilimumab 4mirvetuximab soravtansine 3ipatasertib 3defactinib 3cediranib 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Ovarian Neoplasms × cediranib × Clear all
NCT02446600 2026-06-03

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
579 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02345265 2026-05-28

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
70 enrolled 16 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-04-29

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡